ECM
AMRX icon

EMC Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

EMC Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31,090
Closed -$261K – 309
2025
Q1 		$261K Hold
31,090
– – 0.16% 107
2024
Q4 		$246K Hold
31,090
– – 0.14% 125
2024
Q3 		$259K Hold
31,090
– – 0.17% 118
2024
Q2 		$197K Hold
31,090
– – 0.11% 160
2024
Q1 		$188K Sell
31,090
-9,523
-23% -$53.7K 0.11% 178
2023
Q4 		$247K Hold
40,613
– – 0.17% 113
2023
Q3 		$171K Buy
40,613
+36,497
+887% +$136K 0.13% 151
2023
Q2 		$164K Sell
4,116
-36,497
-90% -$77.8K 0.13% 156
2023
Q1 		$56K Hold
40,613
– – 0.05% 249
2022
Q4 		$81K Hold
40,613
– – 0.07% 242
2022
Q3 		$82K Hold
40,613
– – 0.08% 218
2022
Q2 		$129K Buy
40,613
+196
+0.5% +$710 0.11% 196
2022
Q1 		$156K Buy
+40,417
New +$179K 0.11% 149

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EMC Capital Management's AMRX Position: Q2 2025 in Review

EMC Capital Management sold out of Amneal Pharmaceuticals (AMRX) in Q2 2025, closing a stake of 31,090 shares — an estimated $261K sold.

EMC Capital Management first reported a position in AMRX in Q1 2022 and held it in 13 quarters. The position peaked at $261K in Q1 2025. 241 funds tracked by Wall St. Rank hold AMRX as of Q2 2025.

  • EMC Capital Management reported no remaining Amneal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • EMC Capital Management sold 31,090 Amneal Pharmaceuticals shares in Q2 2025, an estimated $261K.
  • EMC Capital Management first reported a position in Amneal Pharmaceuticals in Q1 2022 and held it in 13 quarters.
  • EMC Capital Management's Amneal Pharmaceuticals position peaked at $261K in Q1 2025.
  • 241 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2025.

Based on EMC Capital Management's 13F filing for Q2 2025, filed 11 Aug 2025.